The FDA has cleared LumosityRx to improve attention function in adults aged 22 to 55 years with primarily inattentive or combined-type ADHD.
Lumos Labs, creators of the popular Lumosity brain training platform with over 100 million users, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback